+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck



Phase I study of cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck



EJC Suppl.s 1(5): S34




(PDF emailed within 1 workday: $29.90)

Accession: 035489535

Download citation: RISBibTeXText


Related references

Phase I/II study of cetuximab in combination with cisplatin or carboplatin and fluorouracil in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 24(18): 2866-2872, 2006

Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil (5-FU) in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R&M SCCHN) (EXTREME). Journal of Clinical Oncology 24(18_Suppl): 5537-5537, 2016

Approval summary: Cetuximab in combination with cisplatin or carboplatin and 5-fluorouracil for the first-line treatment of patients with recurrent locoregional or metastatic squamous cell head and neck cancer. Oncologist 18(4): 460-466, 2014

Phase Ib trial of the Toll-like receptor 9 agonist IMO-2055 in combination with 5-fluorouracil, cisplatin, and cetuximab as first-line palliative treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs 31(5): 1207-1216, 2014

Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?. Journal of Cancer Research and Therapeutics 13(3): 510-513, 2018

Phase 1 and pharmacokinetic study of everolimus in combination with cetuximab and carboplatin for recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer 120(24): 3940-3951, 2015

Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck. European Journal of Cancer 49(13): 2877-2883, 2013

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part). Annals of Oncology 25(3): 682-688, 2014

Cetuximab-Carboplatin-5-Fluorouracil Regimen in Elderly Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A French Retrospective Survey. Oncology 93(1): 11-17, 2017

Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02). Annals of Oncology 29(4): 1004-1009, 2018

Phase Ib study of duligotuzumab (MEHD7945A) plus cisplatin/5-fluorouracil or carboplatin/paclitaxel for first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck. Cancer 122(24): 3803-3811, 2016

Carboplatin/5-fluorouracil as an alternative to cisplatin/5- fluorouracil for metastatic and recurrent head and neck squamous cell carcinoma and nasopharyngeal carcinoma. Asian Pacific Journal of Cancer Prevention 14(2): 1121-1126, 2014

Phase II trial of a combination of low dose cisplatin (DDP) and bolus 5-fluorouracil (FU) in recurrent and metastatic squamous cell carcinoma of the head and neck. European Journal of Cancer and Clinical Oncology 22(7): 891-892, 1986

Phase ii trial of a combination of low dose cisplatin and bolus 5 fluorouracil in recurrent and metastatic squamous cell carcinoma of the head and neck. Cancer Immunology Immunotherapy 18(SUPPL): S14, 1984

Treatment of recurrent and/or metastatic squamous cell head and neck carcinoma with a combination of vinorelbine, cisplatin, and 5-fluorouracil: a multicenter phase II trial. Annals of Oncology 6(10): 987-991, 1995